文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

脑膜瘤生长抑素受体表达的脑特异性定量:SUVmax与SUVRsss作为Krenning评分的定量相关指标

Brain-Specific Quantification of Somatostatin Receptor Expression: SUVmax and SUVRsss as Quantitative Correlates of the Krenning Score in Meningioma.
PubMed 文献 · J Nucl Med · 2026-10-15

本研究为单机构回顾性研究,纳入44例患者共70个脑膜瘤,评估[68Ga]Ga-DOTATATE PET的SUVmax与以矢状窦为参照的SUVRsss同Krenning评分的关系。结果显示两者与Krenning评分强相关,SUVRsss与SUVmax的Spearman ρ分别为0.70与0.77(P<0.0001),并得出区分Krenning 2对3及3对4的最佳阈值,提示脑特异性定量参数可作为视觉分级的补充。

要点

  • SUVRsss与SUVmax均与Krenning评分强相关(ρ=0.70与0.77,P<0.0001)。
  • SUVRsss区分Krenning 2对3阈值为9.00(AUC 0.86),3对4为29.84(AUC 0.98)。
  • SUVmax对应阈值分别为7.20(AUC 0.92)与30.70(AUC 0.98)。

核心结论

  • SUVRsss与SUVmax是[68Ga]Ga-DOTATATE PET可见且MRI可测量脑膜瘤Krenning评分2–4的互补定量相关指标。
  • 仅行脑部PET评估可能替代基于肝脾的视觉分级,并在特定情形下减少全身成像需求。
  • ROC曲线衍生的SUV阈值对应肽受体放射性核素治疗资格判定的Krenning评分,支持进一步评估定量PET参数用于脑膜瘤诊疗决策。

研究设计与样本

  • 单机构回顾性研究,纳入44例患者共70个脑膜瘤,均接受临床顶点至大腿的[68Ga]Ga-DOTATATE PET/CT。
  • 从配准的PET与MR图像提取SUVmax、SUVRsss与病灶大小等定量参数。
  • 采用Spearman秩相关分析影像变量与Krenning评分的关联,并以Kruskal-Wallis检验及Holm-Bonferroni校正的Mann-Whitney U检验比较各Krenning类别间定量参数差异。
  • 采用ROC曲线及Youden J指数确定临床相关阈值(Krenning评分<3对≥3、3对4)的最佳 cutoff。

主要发现

  • SUVRsss与Krenning评分强相关(Spearman ρ=0.70;95%CI 0.55-0.82)。
  • SUVmax与Krenning评分强相关(Spearman ρ=0.77;95%CI 0.64-0.85;P<0.0001)。
  • PET参数在各Krenning类别间差异显著(均P<0.001)。

关键数值与推荐

  • SUVRsss区分Krenning评分2对3的最佳阈值为9.00(AUC 0.86;95%CI 0.74-0.96)。
  • SUVRsss区分Krenning评分3对4的最佳阈值为29.84(AUC 0.98;95%CI 0.93-1.00)。
  • SUVmax区分Krenning评分2对3的最佳阈值为7.20(AUC 0.92;95%CI 0.84-0.99)。
  • SUVmax区分Krenning评分3对4的最佳阈值为30.70(AUC 0.98;95%CI 0.95-1.00)。

临床怎么用

  • 对[68Ga]Ga-DOTATATE PET可见且MRI可测量的脑膜瘤,可用SUVRsss与SUVmax作为Krenning评分的定量补充。
  • 在特定情形下可考虑仅行脑部PET评估,以减少全身成像需求。
  • ROC衍生SUV阈值对应肽受体放射性核素治疗资格判定的Krenning评分,可支持诊疗一体化决策的进一步评估。

局限性

  • 本研究为单机构回顾性研究,样本量为44例患者、70个脑膜瘤。
  • 结论仅适用于[68Ga]Ga-DOTATATE PET可见且MRI可测量的脑膜瘤。
  • 定量阈值用于诊疗决策仍需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor type 2 is highly expressed in meningiomas and can be quantified using [68Ga]Ga-DOTATATE PET. The Krenning score, originally developed for [111In]In-octreotide scintigraphy, remains the standard visual grading system for somatostatin receptor expression and is widely used to guide eligibility for peptide receptor radionuclide therapy. However, visual grading may not optimally translate to intracranial disease. This study evaluated the relationship between brain-specific quantitative PET parameters-SUVmax and SUV ratio normalized to the superior sagittal sinus (SUVRsss)-and the Krenning score in meningioma. Methods: This single-institution retrospective study included 44 patients (70 meningiomas) who underwent clinical vertex-to-thigh [68Ga]Ga-DOTATATE PET/CT. Quantitative parameters (SUVmax, SUVRsss, lesion size) were extracted from coregistered PET and MR images. Spearman rank correlation analysis was performed to assess associations between imaging variables and Krenning score. Differences in quantitative PET parameters across Krenning categories were evaluated using Kruskal-Wallis test and Holm-Bonferroni-corrected Mann-Whitney U test. Receiver-operating-characteristic curve analysis using the Youden J index identified optimal cutoffs for clinically relevant thresholds (Krenning score of <3 vs. ≥3 and 3 vs. 4). Results: SUVRsss and SUVmax were strongly correlated with the Krenning score (SUVRsss: Spearman ρ = 0.70; 95% CI, 0.55-0.82; SUVmax: Spearman ρ = 0.77; 95% CI, 0.64-0.85; P < 0.0001). PET parameters differed significantly across Krenning categories (all P < 0.001). SUVRsss optimal thresholds were 9.00 (area under the curve [AUC], 0.86; 95% CI, 0.74-0.96) for Krenning scores of 2 versus 3 and 29.84 (AUC, 0.98; 95% CI, 0.93-1.00) for Krenning scores of 3 versus 4. SUVmax optimal thresholds were 7.20 (AUC, 0.92; 95% CI, 0.84-0.99) and 30.70 (AUC, 0.98; 95% CI, 0.95-1.00), respectively. Conclusion: SUVRsss and SUVmax are complementary quantitative correlates of Krenning scores 2-4 in [68Ga]Ga-DOTATATE PET-visible, MRI-measurable meningiomas. Brain-only PET evaluation may provide an alternative to liver- and spleen-based visual grading and reduce the need for whole-body imaging in selected settings. Receiver-operating-characteristic curve-derived SUV thresholds correspond to Krenning scores used for eligibility for treatment with peptide receptor radionuclide therapy, supporting further evaluation of quantitative PET parameters for theranostic decision-making for patients with meningioma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Marulanda-Corzo V, Farid M, Hill T, et al. Brain-Specific Quantification of Somatostatin Receptor Expression: SUVmax and SUVRsss as Quantitative Correlates of the Krenning Score in Meningioma. J Nucl Med. 2026. PMID: 42880959. doi:10.2967/jnumed.126.272351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。